Table 2.
Comparison of length of hospital stay and discharge medication between the two groups.
| Characteristics | Control group (n = 50) | Intensive group (n = 50) | P value |
|---|---|---|---|
| Length of hospital stay, days | 7 [7, 8] | 7 [6, 8] | 0.257 |
| Aspirin, n (%) | 50 (100%) | 50 (100%) | 1 |
| Ticagrelor, n (%) | 28 (56%) | 31 (62%) | 0.542 |
| Clopidogrel, n (%) | 22 (44%) | 19 (38%) | 0.542 |
| ACEI/ARB/ARNI, n (%) | 47 (94%) | 48 (96%) | 0.646 |
| β-blocker, n (%) | 42 (84%) | 45 (90%) | 0.372 |
| MRA, n (%) | 6 (12%) | 9 (18%) | 0.401 |
| SGLT2i, n (%) | 15 (30%) | 19 (38%) | 0.398 |
| GLP-1RA, n (%) | 6 (12%) | 8 (16%) | 0.564 |
| NOAC, n (%) | 4 (8%) | 3 (6%) | 0.695 |
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ARNI, angiotensin receptor-neprilysin inhibitor; MRA, mineralocorticoid receptor antagonist; SGLT2i, sodium-glucose cotransporter 2 inhibitor; GLP-1RA, glucagon-like peptide-1 receptor agonist; NOAC, novel oral anticoagulants.